GSK plc (GSK)

GSK beat estimates for both earnings and sales. The decline in sales of the General Medicines segment due to legacy drug sales declines probably made investors more cautious about the company’s long-term growth outlook. Despite the recent weakness, GSK still has strong fundamentals. The recent pullb…

Sie befinden sind hier: Startseite > Börse > Ueberblick > GlaxoSmithKline Pharma stock (INE159A01016): Indian ... ... GlaxoSmithKline Pharma, the India-listed arm of global healthcare group GSK, remains in focus for investors after its latest quarterly earnings and dividend actions, highlighting ...

To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page. ... According to Spark, TipRanks’ AI Analyst, GSK is a Neutral. The score is driven primarily by solid underlying financial performance (strong margins and improved earnings) and supportive ...

All guidance, outlooks and expectations should be read together with the guidance and outlooks, assumptions and cautionary statements in this Q1 2026 earnings release and in the Group's 2025 Annual Report on Form 20-F.

Glaxo (GSK) delivered earnings and revenue surprises of +7.36% and +0.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?